Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment
Breast cancer is the most common invasive tumor in women and the second leading cause of cancer-related death. Nanomedicine raises high expectations for millions of patients as it can provide better, more efficient, and affordable healthcare, and it has the potential to develop novel therapeutics fo...
Main Authors: | Alberto Juan, Francisco J. Cimas, Iván Bravo, Atanasio Pandiella, Alberto Ocaña, Carlos Alonso-Moreno |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-08-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/17/6018 |
Similar Items
-
An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy
by: Alberto Juan, et al.
Published: (2020-08-01) -
Targeted Anticancer Agent with Original Mode of Action Prepared by Supramolecular Assembly of Antibody Oligonucleotide Conjugates and Cationic Nanoparticles
by: Victor Lehot, et al.
Published: (2023-06-01) -
Antibody–siRNA conjugates (ARC): Emerging siRNA drug formulation
by: Weiran Cao, et al.
Published: (2022-09-01) -
Business Risk Mitigation in the Development Process of New Monoclonal Antibody Drug Conjugates for Cancer Treatment
by: Balázs Kiss, et al.
Published: (2023-06-01) -
Antibody–Drug Conjugates for the Treatment of Breast Cancer
by: Chiara Corti, et al.
Published: (2021-06-01)